Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Successful conclusion of phase I trial of ZP-120

Jan. 10, 2003

NexMed completes dosing in two-year rat carcinogenicity study

Jan. 7, 2003

License agreement for Befar in South Korea

Dec. 30, 2002

Two pivotal phase III trials of Alprox-TD completed

Dec. 18, 2002

RenaZorb begins testing in animals

Dec. 12, 2002

European approval for Avodart for benign prostatic hyperplasia

Dec. 11, 2002

Lilly and Boehringer Ingelheim sign cocommercialization agreements for duloxetine

Dec. 10, 2002

Lilly Icos presents new PDE5 inhibitors for male and female sexual dysfunction

Dec. 9, 2002

Marketing authorization application submitted for Striant in U.K.

Dec. 9, 2002

ZP-120 completes phase I trial

Dec. 9, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...